Patents by Inventor Pamela B. Davis

Pamela B. Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090118337
    Abstract: A method of treating a subject with a cystic fibrosis related disorder includes administering a therapeutically effective amount of at least one PPAR? agonist or a derivative thereof.
    Type: Application
    Filed: June 2, 2006
    Publication date: May 7, 2009
    Inventor: Pamela B. Davis
  • Publication number: 20040152653
    Abstract: Serpin enzyme complex receptors are used as targets for therapeutic drugs in the lungs and brain tissue. Any lung or brain disease and any therapeutic drug can be targeted to the lung or brain by use of ligands which specifically bind to the receptors. Complexes for delivery may include proteins, pharmacological agents, or nucleic acids, as well as carrier molecules, and ligands for the receptors. The ligands can be coupled directly to the therapeutic agent or to a carrier molecule which binds to the therapeutic agent.
    Type: Application
    Filed: November 7, 2003
    Publication date: August 5, 2004
    Applicant: Case Western Reserve University
    Inventors: Assem Ziady, Pamela B. Davis, Thomas W. Ferkol, Alfred Malouf
  • Patent number: 6770739
    Abstract: Phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR) by cyclic AMP-dependent protein kinase (PKA) is essential for opening the CFTR chloride channel. A short segment containing many negatively charged amino acids (817-838, NEG2) within the regulatory (R) domain of CFTR is a critical regulator of the chloride channel activity. Deletion of NEG2 from CFTR completely eliminates the PKA dependence of the chloride channel. Exogenous NEG2 peptide interacts with the CFTR molecule and exhibits stimulatory effects on CFTR function. Our data suggest that NEG2 interacts with other cytosolic domains of CFTR to control the opening transitions of the chloride channel.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: August 3, 2004
    Assignee: Case Western Reserve University
    Inventors: Lynn Adams, Pamela B. Davis, Jian Jie Ma
  • Publication number: 20040121957
    Abstract: Phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR) by cyclic AMP-dependent protein kinase (PKA) is essential for opening the CFTR chloride channel. A short segment containing many negatively charged amino acids (817-838, NEG2) within the regulatory (R) domain of CFTR is a critical regulator of the chloride channel activity. Deletion of NEG2 from CFTR completely eliminates the PKA dependence of the chloride channel. Exogenous NEG2 peptide interacts with the CFTR molecule and exhibits stimulatory effects on CFTR function. Our data suggest that NEG2 interacts with other cytosolic domains of CFTR to control the opening transitions of the chloride channel.
    Type: Application
    Filed: December 23, 2003
    Publication date: June 24, 2004
    Applicant: Case Western Reserve University
    Inventors: Lynn Adams, Pamela B. Davis, Jian Jie Ma
  • Patent number: 6287817
    Abstract: A protein conjugate consisting of antibody directed at the pIgR and A1AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: September 11, 2001
    Assignee: Case Western Reserve University
    Inventors: Pamela B. Davis, Thomas Ferkol, Elizabeth Eckman, John Schreiber, John M. Luk
  • Patent number: 6261787
    Abstract: A bifunctional molecule consisting of a therapeutic molecule and a ligand which specifically binds a transcytotic receptor can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides the ability to deliver a therapeutic molecule directly to the apical surface of the epithelium, by targeting the transcytotic receptor with an appropriate ligand. Thus, the highest concentration of the therapeutic molecule will be at the apical surface, where it can have the greatest therapeutic effect.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: July 17, 2001
    Assignee: Case Western Reserve University
    Inventors: Pamela B. Davis, Thomas W. Ferkol, Jr., Elizabeth Eckman
  • Patent number: 6200801
    Abstract: Nucleic acids are compacted, substantially without aggregation, to facilitate their uptake by target cells of an organism to which the compacted material is administered. The nucleic acids may achieve a clinical effect as a result of gene expression, hybridization to endogenous nucleic acids whose expression is undesired, or site-specific integration so that a target gene is replaced, modified or deleted. The targeting may be enhanced by means of a target cell-binding moiety. The nucleic acid is preferably compacted to a condensed state.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: March 13, 2001
    Assignee: Case Western Reserve University
    Inventors: Thomas W. Ferkol, Jr., Pamela B. Davis, Assem-Galal Ziady
  • Patent number: 6072041
    Abstract: A protein conjugate consisting of antibody directed at the pIgR and A.sub.1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: June 6, 2000
    Assignee: Case Western Reserve University
    Inventors: Pamela B. Davis, Thomas Ferkol, Elizabeth Eckman, John Schreiber, John M. Luk
  • Patent number: 5972900
    Abstract: Nucleic acids are compacted, substantially without aggregation, to facilitate their uptake by target cells of an organism to which the compacted material is administered. The nucleic acids may achieve a clinical effect as a result of gene expression, hybridization to endogenous nucleic acids whose expression is undesired, or site-specific integration so that a target gene is replaced, modified or deleted. The targeting may be enhanced by means of a target cell-binding moiety. The nucleic acid is preferably compacted to a condensed state.
    Type: Grant
    Filed: June 3, 1996
    Date of Patent: October 26, 1999
    Assignee: Case Western Reserve University
    Inventors: Thomas W. Ferkol, Jr., Pamela B. Davis
  • Patent number: 5972901
    Abstract: Nucleic acids are compacted, substantially without aggregation, to facilitate their uptake by target cells of an organism to which the compacted material is administered. The nucleic acids may achieve a clinical effect as a result of gene expression, hybridization to endogenous nucleic acids whose expression is undesired, or site-specific integration so that a target gene is replaced, modified or deleted. The targeting may be enhanced by means of a target cell-binding moiety. The nucleic acid is preferably compacted to a condensed state.
    Type: Grant
    Filed: June 3, 1996
    Date of Patent: October 26, 1999
    Assignee: Case Western Reserve University
    Inventors: Thomas W. Ferkol, Jr., Pamela B. Davis, Assem-Galal Ziady